R&D | April 12, 2026
Touchlight and SVF partner to advance next-gen Hepatitis B/D vaccine development
The company says the platform offers improved manufacturability and functional advantages
The company says the platform offers improved manufacturability and functional advantages
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
Three-day programme equips CSIR researchers with advanced AI tools, molecular docking insights, and biomolecular simulation expertise
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Subscribe To Our Newsletter & Stay Updated
